Screening for Liver Disease - are LFTs Old HAT?
Authors: Lo, Robert; Rye, Kara; Austin, Andrew; Freeman, Jan
Source: Current Medicinal Chemistry, Volume 16, Number 12, April 2009 , pp. 1442-1450(9)
Publisher: Bentham Science Publishers
Abstract:The economic burden of end stage liver disease is set to increase due to the rising prevalence of cirrhosis secondary to alcohol, viral hepatitis and fatty liver disease. Screening for liver disease has been advocated, as most cases of cirrhosis are preventable with early interventions. Liver function tests (LFTs) are routinely used as a first line investigation to screen for liver diseases but can be normal despite significant underlying liver fibrosis, hepatitis, steatohepatitis or even cirrhosis. Their relationships are far from linear and with little predictive value in some cases. Newer non-invasive modalities are emerging but currently their roles are largely experimental. This review will discuss the role of serum biomarkers and imaging techniques as new modalities to screen for liver disease.
Document Type: Research Article
Affiliations: Digestive Diseases Centre, Derby Hospitals NHS Foundation Trust, Derby DE22 3NE, UK.
Publication date: 2009-04-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.